MedTrace Logo

The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II

NCT03947879 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-05-13

No results posted yet for this study

Summary

The study is an initial non-blinded, non-placebo controlled trial to determine the efficacy of L-glutamine in lowering blood sugar in patients with diabetes mellitus type II without sickle cell anemia.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

L-glutamine

15 g of L-glutamine twice daily by mouth for 3 months.

OTHER

No L-glutamine

The same patients will be given no L-glutamine for 3 months.

Sponsors & Collaborators

  • Hawaii Pacific Health

    lead OTHER

Principal Investigators

  • Charles Zerez, MD, PhD · Straub Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2021-05-31
Completion
2022-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03947879 on ClinicalTrials.gov